The U.S. Food and Drug Administration (FDA) announced on May 13, 2025, that it will begin recalling prescription medications containing ingestible fluoride for children.

Unlike products such as toothpaste or mouthwash, which also contain fluoride but are not swallowed, these medications are designed to be ingested by infants and young children.

The FDA justified its decision by noting that these products have never been approved by the agency and that ingestible fluoride can disrupt the gut microbiome, a particularly delicate area during the early stages of child development.

WHOM DOES THIS IMPACT?

The direct impact is on minor patients, parents and caregivers, healthcare professionals, pharmaceutical manufacturers, health authorities, and legislators.

CONCLUSION:

The impact is significant because it alters clinical practices, affects children's health, generates pressure on medical and regulatory sectors, and could alter public perceptions about fluoride use. Although it does not affect the entire population, its impact on a sensitive group and its ability to change long-term policies give it considerable relevance.